| Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models SE Grimm, X Pouwels, BLT Ramaekers, B Wijnen, S Knies, J Grutters, ... PharmacoEconomics 38 (2), 205-216, 2020 | 29 | 2020 |
| Arsenic trioxide for treating acute promyelocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal BLT Ramaekers, R Riemsma, S Grimm, D Fayter, S Deshpande, ... Pharmacoeconomics, 1-8, 2019 | 20 | 2019 |
| Uncertainty and coverage with evidence development: does practice meet theory? XGLV Pouwels, JPC Grutters, J Bindels, BLT Ramaekers, MA Joore Value in Health 22 (7), 799-807, 2019 | 19 | 2019 |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis: an evidence review group perspective of a NICE single technology appraisal XGLV Pouwels, S Petersohn, VH Carrera, AK Denniston, A Chalker, ... PharmacoEconomics 38 (5), 431-441, 2020 | 16 | 2020 |
| Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal BLT Ramaekers, RF Wolff, X Pouwels, M Oosterhoff, A Van Giessen, ... Pharmacoeconomics 36 (8), 917-927, 2018 | 13 | 2018 |
| Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study S Petersohn, X Pouwels, B Ramaekers, A ten Cate-Hoek, M Joore European Journal of Preventive Cardiology, 2047487320913380, 2020 | 11 | 2020 |
| Nivolumab for treating metastatic or unresectable urothelial cancer: an evidence review group perspective of a NICE single technology appraisal SE Grimm, N Armstrong, BLT Ramaekers, X Pouwels, S Lang, ... Pharmacoeconomics 37 (5), 655-667, 2019 | 11 | 2019 |
| Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State … IEH Kremer, M Hiligsmann, J Carlson, M Zimmermann, PJ Jongen, ... Medical Decision Making 40 (8), 1003-1019, 2020 | 9 | 2020 |
| Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer XGLV Pouwels, BLT Ramaekers, MA Joore Breast cancer research and treatment 165 (3), 485-498, 2017 | 9 | 2017 |
| An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry XGLV Pouwels, BLT Ramaekers, SME Geurts, F Erdkamp, BEPJ Vriens, ... Acta Oncologica 59 (9), 1123-1130, 2020 | 8 | 2020 |
| Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands PP Schneider, XGLV Pouwels, VL Passos, BLT Ramaekers, SME Geurts, ... PloS one 15 (4), e0230909, 2020 | 8 | 2020 |
| Pembrolizumab for treating relapsed or refractory classical hodgkin lymphoma: an evidence review group perspective of a NICE single technology appraisal SE Grimm, D Fayter, BLT Ramaekers, S Petersohn, R Riemsma, ... Pharmacoeconomics, 1-13, 2019 | 7 | 2019 |
| Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation SE Grimm, X Pouwels, BLT Ramaekers, NT van Ravesteyn, ... Value in Health, 2021 | 6 | 2021 |
| Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal XGLV Pouwels, R Wolff, BLT Ramaekers, A Van Giessen, S Lang, ... PharmacoEconomics 36 (5), 533-543, 2018 | 6 | 2018 |
| The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry X Pouwels, SME Geurts, BLT Ramaekers, F Erdkamp, B Vriens, ... Acta Oncologica 59 (1), 82-89, 2020 | 5 | 2020 |
| State of the ART? Two New Tools for Risk Communication in Health Technology Assessments SE Grimm, X Pouwels, BLT Ramaekers, B Wijnen, T Otten, J Grutters, ... PharmacoEconomics, 1-12, 2021 | 4 | 2021 |
| Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands PP Schneider, BL Ramaekers, X Pouwels, S Geurts, K Ibragimova, ... Value in Health 24 (5), 668-675, 2021 | 4 | 2021 |
| Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma: an evidence review group perspective of a NICE single technology appraisal WJA Witlox, SE Grimm, R Riemsma, N Armstrong, S Ryder, S Duffy, ... Pharmacoeconomics 39 (2), 171-180, 2021 | 4 | 2021 |
| Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal BLT Ramaekers, R Wolff, A van Giessen, X Pouwels, D Fayter, S Lang, ... PharmacoEconomics 36 (3), 285-288, 2018 | 4 | 2018 |
| Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence … SE Grimm, X Pouwels, BLT Ramaekers, B Wijnen, S Knies, J Grutters, ... Orphanet Journal of Rare Diseases 16 (1), 1-7, 2021 | 3 | 2021 |
